A comparison of basiliximab and anti-thymocyte globluin as induction agents after lung transplantation

Journal of Heart and Lung Transplantation

Volumn 24, Issue 9, 2005, Pages 1320-1326

  Hachem, Ramsey R ^a   Chakinala, Murali M ^a   Yusen, Roger D ^a   Lynch, John P ^a   Aloush, Aviva A ^a   Patterson, G Alexander ^a   Trulock, Elbert P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; BRONCHIOLITIS OBLITERANS; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; HEALTH CENTER; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RECIPIENT; RETROSPECTIVE STUDY; SCORING SYSTEM; VIREMIA;

ADULT; ANTIBODIES, MONOCLONAL; ANTILYMPHOCYTE SERUM; BRONCHIOLITIS OBLITERANS; BRONCHOSCOPY; CYTOMEGALOVIRUS INFECTIONS; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUNG DISEASES; LUNG TRANSPLANTATION; MIDDLE AGED; PNEUMONIA; RECEPTORS, INTERLEUKIN-2; RECOMBINANT FUSION PROTEINS; REPERFUSION INJURY; RETROSPECTIVE STUDIES;

EID: 24344440228     PISSN: 10532498     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.healun.2004.09.002     Document Type: Article

References (21)

1. E.P. Trulock, L.B. Edwards, D.O. Taylor The Registry of the International Society for Heart and Lung Transplantation Twentieth Official Adult Lung and Heart-Lung Transplant Report-2003 J Heart Lung Transplant 22 6 2003 625 635
2. A.N. Husain, M.T. Siddiqui, E.W. Holmes Analysis of risk factors for the development of bronchiolitis obliterans syndrome Am J Respir Crit Care Med 159 1999 829 833
3. L.D. Sharples, K. McNeil, S. Stewart, J. Wallwork Risk factors for bronchiolitis obliterans a systematic review of recent publications J Heart Lung Transplant 21 2002 271 281
4. M. Estenne, J.R. Maurer, A. Boehler Bronchiolitis obliterans syndrome 2001 an update of the diagnostic criteria J Heart Lung Transplant 21 2002 297 310
5. B.P. Griffith, R.L. Hardesty, J.M. Armitage Acute rejection of lung allografts with various immunosuppressive protocols Ann Thorac Surg 54 1992 846 851
6. S.M. Palmer, A.P. Miralles, C.M. Lawrence, J.W. Gaynor, R.D. Davis, V.F. Tapson Rabbit antithymocyte globulin decreases acute rejection after lung transplantation results of a randomized prospective study Chest 116 1999 127 133
7. E.R. Garrity, J. Villanueva, S.M. Bhorade, A.N. Husain, W.T. Vigneswaran Low rate of acute lung allograft rejection after the use of daclizumab, an interleukin 2 receptor antibody Transplantation 71 2001 773 777
8. B. Charpentier, L. Rostaing, F. Berthoux A three-arm study comparing immediate tacrolimus therapy with anti-thymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients Transplantation 75 6 2003 844 851
9. C. Duvoux, G.P. Pageaux, C. Vanlemmens Risk factors for lymphoproliferative disorders after liver transplantation in adults an analysis of 480 patients Transplantation 74 8 2002 1103 1109
10. M.V. Brock, M.C. Borja, L. Ferber Induction therapy in lung transplantation a prospective, controlled clinical trial comparing OKT3, anti-thymocyte globulin, and daclizumab J Heart Lung Transplant 20 2001 1282 1290
11. R.R. Hachem, G.A. Patterson, E.P. Trulock Comparison of basiliximab and anti-thymocyte globulin as induction agents after lung transplantation [abstract] J Heart Lung Transplant 23 2004 A211
12. S.A. Yousem, G.J. Berry, P.T. Cagle Lung Rejection Study Group Revision of the 1990 working formulation for the classification of pulmonary allograft rejection J Heart Lung Transplant 15 1996 1 15
13. J.D. Cooper, M. Billingam, T. Egan International Society for Heart and Lung Transplantation A working formulation for the standardization of nomenclature for clinical staging of chronic allograft dysfunction in lung allografts J Heart Lung Transplant 12 1993 713 716
14. Chakinala MM, Ritter J, Gage BF, et al. Reliability for grading acute rejection and airway inflammation after lung transplantation. J Heart Lung Transplant (In press).
15. P.M. Hopkins, C.L. Aboyoun, P.N. Chhajed Outcome of minimal acute rejection (grade A1) in lung transplant recipients the need for careful observation [abstract] J Heart Lung Transplant 21 2002 A144
16. R.E. Girgis, I. Tu, G.J. Berry Risk factors for the development of obliterative bronchiolitis after lung transplantation J Heart Lung Transplant 15 1996 1200 1208
17. S.M. Fiser, C.G. Tribble, S.M. Long Ischemia-reperfusion injury after lung transplantation increases risk of late bronchiolitis obliterans syndrome Ann Thorac Surg 73 2002 1041 1048
18. B.D. Kahan, P.R. Rajagopalan, M. Hall Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody Transplantation 67 1999 276 284
19. H. Sollinger, B. Kaplan, M.D. Pescovitz Basiliximab versus anti-thymocyte globulin for prevention of acute renal allograft rejection Transplantation 72 2001 1915 1919
20. B. Kircher, K. Latzer, G. Gastl, D. Nachbaur Comparative in vitro study of the immunomodulatory activity of humanized and chimeric anti-CD 25 monoclonal antibodies Clin Exp Immunol 134 2003 426 430
21. th ed. 2003 Medical Economics Co Montvale, NJ